Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Inclusion Criteria:

- Informed consent obtained

- Body Mass Index (BMI) of 30.0 kg/m^2 or above

- Body Mass Index (BMI) of 27 kg/m^2 or above in the presence of co-morbidities of
treated or untreated dyslipidemia and/or hypertension

- Stable body weight

- Preceding failed dietary effort

Exclusion Criteria:

- Known type 1 or type 2 diabetes

- Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126
mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma
glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)

- Screening calcitonin of 50 ng/L or above

- Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
medullary thyroid carcinoma (FMTC)

- Personal history of non-familial medullary thyroid carcinoma

- History of acute or chronic pancreatitis

- Obesity induced by drug treatment

- Use of approved weight lowering pharmacotherapy

- Previous surgical treatment of obesity

- History of major depressive disorder or suicide attempt

- Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or
diastolic blood pressure of 100 mmHg or above)